Evidence map›Paper›PMID 30942129›Full record

ArticleActa cardiologica2020

The prognostic importance of subclinical heart failure in stable coronary heart disease patients.

Petr König, Otto Mayer, Jan Bruthans, Jitka Seidlerová, Markéta Mateřánková, Julius Gelžinský, Martina Rychecká, Petra Karnosová, Peter Wohlfahrt, Renata Cífková and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Acta cardiologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05911724 (Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05911724 completedstarted 2023, after this paper: background citation

Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.

Ran2023Enrolled180Registered outcomes7Posted comparisons0ConditionsHeart Failure, Stable AnginaArmsCAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study, Group I Healthy, HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Petr KönigFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Otto MayerFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Jan BruthansFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Jitka SeidlerováFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Markéta MateřánkováFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Julius GelžinskýFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Martina RycheckáFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Petra KarnosováFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Peter WohlfahrtCentre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer's Hospital, Prague, Czech Republic.
Renata CífkováCentre for Cardiovascular Prevention of the First Faculty of Medicine, Charles University and Thomayer's Hospital, Prague, Czech Republic.
Jan FilipovskýFaculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Charles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Asymptomatic DiseasesHeart FailureDiureticsFemaleHospitalizationHumansMaleMiddle AgedMortalityMyocardial InfarctionMyocardial RevascularizationNatriuretic Peptide, BrainPrognosisProportional Hazards ModelsRisk AssessmentStroke VolumeDiureticsNatriuretic Peptide, BrainEUROASPIREmortalityNatriuretic peptidesrisk estimationsecondary prevention

Identifiers

PMID30942129
OpenAlexW2927826007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.